Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
grnQyGFBrqFHFzMx